

From: Jessica Bulliss <pharma@smiconferences.co.uk>

To: Kester, Tonykester@aging.sc.gov

Date: 9/27/2016 6:55:32 AM

Subject: Introducing RNA Therapeutics 2017 | Agenda Released

---

### RNA Therapeutics 2017

8th annual conference: 22nd & 23rd February | Interactive workshop: 21st February  
Cophorne Tara Hotel, London, UK

[www.therapeutics-rna.com](http://www.therapeutics-rna.com) - **register now live to save £400**

Proudly Sponsored by: Lipocalyx

---

---

### AGENDA RELEASED:

---

---

SMi Group is thrilled to present the 8th annual conference, **RNA Therapeutics**, taking place on **22nd & 23rd February 2017** in Central London, UK. Gathering an audience of principle scientists and senior industry experts involved in targeted delivery systems, RNA Therapeutics 2017 will provide the perfect platform to discuss current developments shaping the industry.

---

---

### ABOUT THE CONFERENCE:

---

---

We have worked closely with a leading panel of experts such as **Roche, MHRA, GSK, MiNA Therapeutics, BioNTech RNA Pharmaceutical, AstraZeneca** and **Novartis**, to create a programme that will expand scientific horizons in topics such as siRNA, oligonucleotides, nucleic acids, individualised mRNA based immunotherapy, antisense in the fourth decade, regulatory guidance on reporting clinical data and patent applications, plus much more!

Take a look at the packed agenda by downloading a [brochure](#) today.

---

---

### EXCEPTIONAL LINE-UP INCLUDES:

---

---

#### Conference Chairs:

- Nagy Habib, Head of Surgery, Co-Founder, Imperial College Healthcare NHS Trust, **MiNA Therapeutics**
- Heinrich Haas, Vice President RNA Formulation & Drug Delivery, **BioNTech RNA Pharmaceuticals**

## Speakers:

- Bo Rode Hansen, Global Head of RNA Therapeutics, **Roche**
- John Johnston, Clinical Assessor Biologicals & Biotechnology Unit, **MHRA**
- Nicole Meisner-Kober, Senior Investigator, RNA Biology, **Novartis Institutes for Biomedical Research**
- Steve Hood, Director, Bioimaging, **GSK**
- David Giljohann, CEO, **Exicure**
- Shai Erlich, Chief Medical Officer & President USA, **Quark Pharmaceuticals Inc**
- Amotz Shemi, CEO, **Silenseed**
- Sanyogitta Puri, Associate Principal Scientist, **AstraZeneca**

[See the full speaker-line-up](#)

---

---

## THIS IS WHY YOU NEED TO ATTEND IN 2017

---

---

- Overcome **challenges in regulation** and **maximise therapeutics manufacturing** by seeing BioNTech up-scale personalized RNA Nanomedicines in cancer Vaccines.
- Gain **practical skills** from MiNA Therapeutics on RNA activation and the **results** of their clinical trials. They will be discussing the impact saRNA is having on patients suffering from liver disease- discover how you too can strengthen your approach to clinical trials.
- AstraZeneca will be exploring **emerging antisense oligonucleotide drugs** and ways in you can improve drug delivery and optimise clinical results.
- Hear from GSK on the progress of their 5 year **IMI COMPACT** project and the **results** of their collaboration with other pharmaceutical companies into the optimisation of oligonucleotide drug delivery.
- Find out how to **strategically plan** and execute a successful clinical study with an exclusive update from Exicure on their unique nucleic acid based topical treatment for psoriasis.

---

---

## HOW TO REGISTER

---

---

Register and **save £400** at [www.therapeutics-rna.com](http://www.therapeutics-rna.com)

For sponsorship enquiries contact Alia Malick on +44 (0)20 7827 6168 or email [amalick@smi-online.co.uk](mailto:amalick@smi-online.co.uk)

For delegate enquiries contact Fateja Begum on +44 (0)20 7827 6184 or email [fbegum@smi-online.co.uk](mailto:fbegum@smi-online.co.uk)

---

---

## WAIT THERE'S MORE!

---

---

Don't forget to check out the pre-conference **interactive workshop** on **Tuesday 21st February 2017** which has been carefully selected to bring you hands on training and complement the topics covered in the conference agenda.

### **Precision Nano-therapeutics: Minding the gap in delivery from preclinical studies to clinical success**

08.30 – 12.30 | Hosted by Professor Andrew David Miller, Professor of Organic Chemistry & Chemical Biology, CSO, **King's College London, KP Therapeutics Ltd**

[www.therapeutics-rna.com](http://www.therapeutics-rna.com)

You are registered as: [kester@aging.sc.gov](mailto:kester@aging.sc.gov) Your Unique Reference Number: 92804565  
To update your contact preferences please go to <http://www.smi-online.co.uk/update-preferences>